0KW4 Stock Chart & Stats
$200.76
$6.94(3.46%)
At close: 4:00 PM EDT
$200.76
$6.94(3.46%)
Day’s Range― - ―
52-Week Range$180.60 - $297.98
Previous CloseN/A
Volume153.00
Average Volume (3M)438.00
Market Cap
$30.60B
Enterprise Value$31.89K
Total Cash (Recent Filing)$1.47B
Total Debt (Recent Filing)$825.92M
Price to Earnings (P/E)20.3
Beta0.62
Next Earnings
Oct 22, 2026EPS Estimate
2.7Next Dividend Ex-DateN/A
Dividend Yield1.15%
Share Statistics
EPS (TTM)10.17
Shares Outstanding145,056,380
10 Day Avg. Volume287
30 Day Avg. Volume438
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$237.91Price Target Upside18.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)12.06
Revenue Forecast (FY)$5.94B
Bulls Say, Bears Say
Bulls Say
High And Improving MarginsSustained high gross margins and a materially improved net margin indicate durable pricing power and cost discipline across the core sleep and respiratory franchises. That profitability supports reinvestment, R&D, and shareholder returns while insulating operating cash flow through typical demand cycles.
Conservative Balance Sheet & Cash GenerationLow leverage and a stronger debt/equity position give ResMed financial flexibility to fund R&D, pursue targeted M&A, sustain buybacks/dividends, and absorb product remediation costs. Combined with historically strong cash conversion, the balance sheet underpins resilient capital allocation over the medium term.
Recurring Consumables & Connected-software EcosystemA large installed device base plus differentiated masks and cloud software create recurring consumable revenue and subscription-led engagement. Higher compliance and digital coaching increase lifetime resupply and stickiness, fostering predictable recurring sales and long-term margin tailwinds.
Bears Say
Astral Ventilator Safety DisruptionThe Astral field‑safety action creates a structural headwind in the life‑support segment, reducing revenue and exposing the business to regulatory scrutiny and remediation costs. Recovery will depend on corrective actions, re‑certification and restored provider confidence, which can take multiple quarters.
Volatile Free Cash FlowMaterial quarter‑to‑quarter FCF swings driven by provisions, working capital shifts and capex increase the risk that capital returns or incremental investments are more cyclical. Persistent FCF variability can pressure buybacks/dividends or delay discretionary product investments over the medium term.
Rising Investment And Portfolio Transition CostsSharpening focus via MatrixCare divestiture and higher R&D/SG&A investment increases near‑term expense and transitional execution risk. While strategic refocus can boost long‑run returns, integration/transitional costs and potential revenue gaps may compress margins before benefits materialize.
Resmed News
0KW4 FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest share price was $180.60 and its highest was $297.98 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $30.60B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Oct 22, 2026 which is in 74 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Aug 06, 2026. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.893 by $0.057.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $0.66 which represents an annual dividend yield of 1.15%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.7.
How many shares outstanding does Resmed have?
Resmed has 145,056,380 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.95 in its last earnings report, beating expectations of $2.893. Following the earnings report the stock price went down -7.836%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in GB:0KW4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$237.91 (18.50% Upside)
$237.91 (18.50% Upside)
Blogger Sentiment
Bullish
GB:0KW4 Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 73%
Bearish news 27%
Bearish news 27%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.90%
12-Months-Change
Fundamentals
Return on Equity
1.15%
Trailing 12-Months
Asset Growth
16.09%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
0KW4 Company Deck
0KW4 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid underlying growth and margin expansion across the core sleep business, strong full-year cash generation, material shareholder returns, and continued product and software momentum (masks, AirSense/AirCurve rollouts, GenAI MyAir, Oura partnership). Key negatives were a sizeable Astral field-safety provision and the suspension of Astral sales (driving significant ventilator revenue declines and near-term revenue/EPS headwinds), higher near-term R&D and SG&A investment, and Q4 free cash flow compression. Management provided explicit FY2027 revenue and EPS guidance, actions to return capital, and plans to prioritize high-ROI investments while actively managing the portfolio—presenting a constructive execution path despite the discrete Astral-related disruption.View all GB:0KW4 earnings summaries0KW4 Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
0KW4 Stock 12 Month Forecast
Average Price Target
$237.91
▲(18.50% Upside)